| Literature DB >> 34472048 |
Mulugeta Russom1,2, Iyassu Bahta3, Merhawi Debesai3.
Abstract
Establishing a mature pharmacovigilance system in a low-income country is a challenge. Nevertheless, Eritrea, one such low-income country, was able to achieve a fully fledged pharmacovigilance system within a period of almost 9 years. In the last five years (2014-2019), the Eritrean Pharmacovigilance Centre has submitted, on average, 646 individual case safety reports (ICSRs) per million inhabitants per year to the World Health Organization (WHO) global database of ICSRs. As a result, Eritrea has been rated among the top reporting countries in Africa. The center has detected about 30 safety signals, achieved maturity level three on the WHO rapid benchmarking assessment, and gained huge political commitment. In the last few years, monitoring of product quality through the pharmacovigilance system found approximately 55 medical products that were either substandard or falsified and were subsequently recalled from the Eritrean market by the National Medicines and Food Administration. The aim of this article is to describe Eritrea's success stories, key strategies for success, challenges encountered, and lessons learned to share them with the international pharmacovigilance community and beyond.Entities:
Mesh:
Year: 2021 PMID: 34472048 DOI: 10.1007/s40264-021-01102-x
Source DB: PubMed Journal: Drug Saf ISSN: 0114-5916 Impact factor: 5.606